BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20638451)

  • 1. Modeling the national pediatric vaccine stockpile: supply shortages, health impacts and cost consequences.
    Shrestha SS; Wallace GS; Meltzer MI
    Vaccine; 2010 Aug; 28(38):6318-32. PubMed ID: 20638451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stockpile levels for pediatric vaccines: how much is enough?
    Jacobson SH; Sewell EC; Proano RA; Jokela JA
    Vaccine; 2006 Apr; 24(17):3530-7. PubMed ID: 16522344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to "Modeling the national pediatric vaccine stockpile: supply shortages, health impacts and cost consequences".
    Proano RA; Jacobson SH; Jokela JA
    Vaccine; 2011 Jan; 29(4):615; author reply 616. PubMed ID: 21094271
    [No Abstract]   [Full Text] [Related]  

  • 4. The United States pediatric vaccine stockpile program.
    Lane KS; Chu SY; Santoli JM
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S125-9. PubMed ID: 16447134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pediatric vaccine stockpiling problem.
    Truong VA
    Vaccine; 2012 Sep; 30(43):6175-9. PubMed ID: 22874852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strengthening the supply of routinely recommended vaccines in the United States: a perspective from the American Medical Association.
    Tan L;
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S121-4. PubMed ID: 16447133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailoring the strategies to specific shortages: pneumococcal conjugate vaccine.
    Peter G
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S138-40. PubMed ID: 16447136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine supply problems: a perspective of the Centers for Disease Control and Prevention.
    Rodewald LE; Orenstein WA; Mason DD; Cochi SL
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S104-10. PubMed ID: 16447130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of the pediatric vaccine supply shortage problem.
    Jacobson SH; Sewell EC; Proano RA
    Health Care Manag Sci; 2006 Nov; 9(4):371-89. PubMed ID: 17186772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatricians' adherence to pneumococcal conjugate vaccine shortage recommendations in 2 national shortages.
    Fairbrother G; Broder K; Staat MA; Schwartz B; Heubi C; Hiratzka S; Walker FJ; Morrow AL
    Pediatrics; 2007 Aug; 120(2):e401-9. PubMed ID: 17646354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine shortages: history, impact, and prospects for the future.
    Hinman AR; Orenstein WA; Santoli JM; Rodewald LE; Cochi SL
    Annu Rev Public Health; 2006; 27():235-59. PubMed ID: 16533116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine supply: a cross-national perspective.
    Danzon PM; Pereira NS; Tejwani SS
    Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
    Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.